BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Piramal Enterprises Ltd. has built a differentiated and robust business model in the pharma space, with an established presence in contract development and manufacturing outsourcing (CDMO, 60% of pharma sales), complex hospital generics (CHG, 30% of Pharma sales), and India consumer products (ICP, 10% of Pharma sales).
After some aberration in the recent past, it is back on the growth path in the pharma space. Its order book has strengthened in the CDMO segment.
The company re-strategized its business, subsequently introduced new products, and increased its distribution reach, thereby driving enhanced revenue growth in the ICP segment.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR